Cypress Bioscience, Inc. (CYPB)
$5.52
-0.01 (-0.18%)
| CAPS Rating |
|
|---|---|
| Open | $5.59 |
| Previous Close | $5.53 |
| Daily Range | $5.49 - $5.65 |
| 52-Week Range | $4.98 - $10.10 |
| Market Cap | $211.39M |
| P/E Ratio | 118.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 436,501 |
| Average Daily Volume | 337,000 |
CYPB
VS S&P 500 (SPY)
How do you think CYPB will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
CYPB Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
CYPB News and Commentary
- UPDATE 1-Cypress Bioscience Q3 loss narrower than expected – Reuters
- Nibbles Here and There at Forest Labs – The Motley Fool
- 6 Stocks Losing Top Investor Support – The Motley Fool
- 5 Stocks Approaching Greatness – The Motley Fool
- Pfizer Doesn't Like Reruns – The Motley Fool
- Lilly's in Need of a Pep Pill – The Motley Fool
- Another Angle for Fibromyalgia – The Motley Fool
- Unloved Stocks Ready to Shine – The Motley Fool
- Four Healthy Stocks Trading Above Moving Averages – Blog at The Motley Fool
- Five Healthcare Stocks Positioned for a Happy New Year – Blog at The Motley Fool
- Updated FDA Calendar: Buying Cypress Bio (CYPB) – Blog at The Motley Fool
- The FDA Can't See the Forest or the Trees – The Motley Fool
- Trading the Trials: Cytori and Cypress Bio – Blog at The Motley Fool
- A Backlog of Decisions is Building at the FDA – Blog at The Motley Fool
- FDA Calendar: Likely Near-Term Movers – Blog at The Motley Fool
- Cypress Bio Poised to Move on Milnacipran Results + FDA Decision – Blog at The Motley Fool
- Likely Big Movers on Pending FDA Decisions – Blog at The Motley Fool
- Cypress Bio Set to Move on Milnacipran FDA Decision + Phase 3 Results – Blog at The Motley Fool
- FDA Calendar of 72 Pending Decision Dates – Blog at The Motley Fool
- Cypress Bioscience: Poised for Major Move on Pending Phase 3 Results and FDA Decision – Blog at The Motley Fool
RSS Headlines
Fool UK
